NSCLC, often the most dreaded of all types of lung cancer, is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. Drugs used in the treatment of NSCLC range from regular regimens to targeted therapies. The drugs are based on simple chemistries to highly advanced complex protein. The market is witnessing strong growth due to high awareness among the population through government initiatives. Moreover, the drugs for NSCLC are given swift approvals by regulatory bodies and grants for research. This has led to new generation of drugs being introduced in the NSCLC market.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1426
The major classes of drugs under NSCLC are angiogenesis inhibitor, EGFR blocker, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitors. The angiogenesis inhibitor segment dominated the market in 2014. High efficacy, targeted therapies, and increasing demand in major geographies such as Europe, the U.S., and Japan are attributed to the dominance of the angiogenesis inhibitor segment in the NSCLC therapeutics market. Zykadia is expected to witness the highest growth rate during the forecast period, followed by Opdivo.
Inquiry on this report @ http://www.mrrse.com/enquiry/1426
Geographically, the NSCLC market segmented into four major regions: North America, Europe, Asia Pacific (APAC), and ROW. North America dominated the global NSCLC therapeutics market in 2014 due to the presence of modern health care infrastructure and an efficient U.S. government system. However, APAC is anticipated to expand at the fastest CAGR during the forecast period. Factors such as increasing population, greater awareness about NSCLC, and growing number of government projects related to lung, cancer, tobacco, and their respective interventions would boost the growth of the market in APAC during the forecast period.
Read Complete Report with TOC @ http://www.mrrse.com/non-small-cell-lung-cancer-market
The NSLCLC therapeutics market exhibits intense competition among existing players. The market is fragmented, characterized by the presence of both generic and branded companies. Major players operating in the NSCLC market are Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, AstraZeneca plc, and Celgene Corporation.
90 State Street,
Albany NY – 12207